Montefiore Medical Center Montefiore Medical Center

About the Procedure

If undetected, this congenital defect can result in death in up to 90% of patients within the first year of life. In this particular case, the child developed enough collateral blood flow to the heart to reach the age of 10.

“This particular girl is an interesting case in that she’s ten years old. Ninety percent of children with this defect will die if undiagnosed within the first year of life. For whatever reason, she was able to develop an extra amount of extra blood sources to her left heart through what we would call collateral vessels, and she survived to be ten years of age,” says Dr Weinstein.

Due to the difficult location of the artery, an intrapulmonary artery baffle was required to redirect oxygenated blood into the vessel from the aorta through an aortopulmonary window. This technique is called the Takeuchi repair.

Dr. Weinstein explains, “Because the vessel itself came off so far away from the aorta, we had to create a tunnel inside the aorta to the pulmonary artery bringing the red oxygenated blood over to that vessel.”

The patient has since been discharged and is doing well postoperatively.

The Montefiore Einstein Heart Center has a rich history of offering distinguished leadership and innovation in the treatment of all kinds of heart disorders. In fact, this year, Montefiore celebrates its 50th year of performing open heart surgery. Montefiore also pioneered breakthrough pacemaker technology and was the first medical center to implant a pacemaker in a human heart as well as the first hospital to install a stent in an aortic aneurism.

Montefiore-Einstein Heart Center has recruited a team of world-renown physicians and surgeons, headed by co-directors Dr. Richard Kitsis and Dr. Robert E. Michler. Currently, any cardiac procedure that is offered anywhere in the world can also be performed at MEHC - from transplant to minimally invasive and robotics.

Active participation in clinical trials and research studies keeps the focus on innovation and progress. MEHC continues to have the only Cardiothoracic Surgery program in the New York metropolitan area enrolling patients in the NHLBI sponsored STICH trial designed for patients with coronary artery disease and heart failure. The experience and skill represented at MEHC with left ventricular reconstruction in patients with dilated ischemic cardiomyopathy is widely recognized and highly regarded world-wide.

MEHC is also among an elite group of centers in the U.S. with the skill and experience to enroll patients in the Marfan’s aortic valve-sparing aneurysm surgery clinical trial. As the only center in the North East with approval to use the new agent Clenbuterol in patients with heart failure, MEHC offers patients with advanced heart failure the latest cutting edge therapies, including the most recent clinical trials for 2nd generation LVAD’s.

Conveniently and centrally located in New York City, Montefiore-Einstein Heart Center is easily accessible from major highway arteries, or through an abundance of mass transit options, or from the major metropolitan airports. The center recently established a “one-stop shopping” transfer center for use by any referring physicians. The line is staffed 24 hours a day/ 7days/week – (1-888 ME HEART). By placing one call, physicians are able to admit or transfer a patient from anywhere in the U.S. and MEHC will handle the logistics.
MDirect Access

 Webcast Links

Digg It! Digg It!

50 Years of Open Heart Surgery